Expanding Subsidies and MediSave Coverage for Biologic Treatments for Atopic Dermatitis and Impact on Patients' Well-being under Chronic Disease Management Programme Review

Ms Valerie Lee asked the Coordinating Minister for Social Policies and Minister for Health (a) whether the ongoing review of atopic dermatitis under the Chronic Disease Management Programme will consider the significant impact of moderate-to-severe disease on patients' associated well-being; and (b) whether the Ministry will consider greater subsidies or MediSave use for clinically indicated treatments, including biologics, particularly for patients who have failed or exhausted conventional treatments.

Mr Ong Ye Kung: The ongoing review does take into account the impact of atopic dermatitis on patients' well-being.

Drugs that have been assessed to be clinically and cost-effective in the management of atopic dermatitis, including clinically- and cost-effective immunosuppressant drugs, such as biologics, are covered by subsidy of up to 75%. Seniors aged 60 and above may use up to $400 under Flexi-MediSave to defray costs after subsidy. Under the Chronic Disease Management Programme, patients may be able to claim up to $700 or $1,000 under the MediSave Chronic and Preventive Care limit from 1 January 2027, depending on whether they have complex chronic conditions.

Patients who continue to have difficulty paying their bills after subsidies and MediSave may seek further assistance, including MediFund, from medical social workers at public healthcare institutions.